Truist Financial Corp Decreases Stock Holdings in Danaher Corporation $DHR

Truist Financial Corp decreased its position in Danaher Corporation (NYSE:DHR) by 1.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 354,272 shares of the conglomerate’s stock after selling 5,215 shares during the quarter. Truist Financial Corp’s holdings in Danaher were worth $69,983,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of DHR. MGO One Seven LLC boosted its stake in shares of Danaher by 485.7% during the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate’s stock valued at $5,145,000 after purchasing an additional 20,813 shares in the last quarter. Chicago Capital LLC boosted its stake in shares of Danaher by 11.6% during the 2nd quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock valued at $2,634,000 after purchasing an additional 1,391 shares in the last quarter. UniSuper Management Pty Ltd boosted its stake in shares of Danaher by 1.6% during the 1st quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock valued at $34,954,000 after purchasing an additional 2,667 shares in the last quarter. Asahi Life Asset Management CO. LTD. bought a new stake in shares of Danaher during the 1st quarter valued at about $539,000. Finally, Horizon Financial Services LLC boosted its stake in shares of Danaher by 20,400.0% during the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate’s stock valued at $1,681,000 after purchasing an additional 8,160 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 7.4%

Shares of NYSE DHR opened at $212.92 on Thursday. The firm’s 50 day moving average price is $199.85 and its 200-day moving average price is $197.42. The company has a market cap of $152.46 billion, a PE ratio of 45.30, a P/E/G ratio of 2.82 and a beta of 0.77. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.41. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. The firm had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business’s revenue was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities research analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s payout ratio is presently 27.23%.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company’s stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 11.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Robert W. Baird lifted their target price on shares of Danaher from $225.00 to $226.00 and gave the company an “outperform” rating in a research note on Friday, July 18th. Guggenheim reissued a “buy” rating and set a $250.00 price objective on shares of Danaher in a research note on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research note on Tuesday, September 2nd. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research note on Friday, June 27th. Finally, Evercore ISI dropped their price objective on shares of Danaher from $230.00 to $226.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 8th. Seventeen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $245.91.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.